Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China flag China · Delayed Price · Currency is CNY
29.93
-0.56 (-1.84%)
Sep 2, 2026, 3:00 PM CST

SHA:603590 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
916.57914.24824.43917.75851.05693.03
Other Revenue
0.480.880.972.2615.68116.76
917.05915.12825.4920.01866.73809.78
Revenue Growth
4.06%10.87%-10.28%6.15%7.03%0.14%
Cost of Revenue
94.1792.2586.26101.05126.65105.76
Gross Profit
822.88822.87739.14818.96740.07704.02
Selling, General & Admin
554.12567.52553.76583.28525.88479.34
Research & Development
71.3751.8654.9494.9186.78102.27
Other Operating Expenses
7.539.046.755.646.048.69
Operating Expenses
632.82639.7620.37689.42620.56591.51
Operating Income
190.07183.17118.77129.54119.51112.51
Interest Expense
-4.21-7.53-6.16-2.78-0.86-1.41
Interest & Investment Income
23.1226.6830.9819.3318.5224.57
Currency Exchange Gain (Loss)
-2.18-3.84-1.290.50.260.31
Other Non Operating Income (Expenses)
-13.43-3.31-1.56-1.7-0.361.58
EBT Excluding Unusual Items
193.38195.16140.74144.9137.06137.57
Impairment of Goodwill
---97.64---
Gain (Loss) on Sale of Investments
6.424.18-0.49-12.78-7.6535.64
Gain (Loss) on Sale of Assets
-0.65-0.52-0.03-0.13-0.010
Asset Writedown
-0.02-0.02-7.77--4.06-
Other Unusual Items
1.73-9.114.05-9.2614.9815.64
Pretax Income
200.86189.6938.86122.73140.32188.86
Income Tax Expense
27.220.2617.33-64.8416.4221.42
Earnings From Continuing Operations
173.65169.4221.53187.57123.89167.44
Minority Interest in Earnings
-3.01-3.4620.69-37.12-22.4-19.46
Net Income
170.64165.9742.22150.45101.49147.99
Net Income to Common
170.64165.9742.22150.45101.49147.99
Net Income Growth
215.66%293.13%-71.94%48.24%-31.42%-19.29%
Shares Outstanding (Basic)
158158156157156157
Shares Outstanding (Diluted)
160160156157156157
Shares Change
2.51%2.06%-0.23%0.37%-0.82%-1.26%
EPS (Basic)
1.081.050.270.960.650.94
EPS (Diluted)
1.071.040.270.960.650.94
EPS Growth
207.91%285.19%-71.88%47.69%-30.85%-18.26%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
79.9362.2368.2298.4423.38-108.43
Free Cash Flow Per Share
0.500.390.440.630.15-0.69
Dividend Per Share
0.3500.3500.6000.3000.2000.300
Dividend Growth
-41.67%-41.67%100.00%50.00%-33.33%-14.29%
Gross Margin
89.73%89.92%89.55%89.02%85.39%86.94%
Operating Margin
20.73%20.02%14.39%14.08%13.79%13.89%
Profit Margin
18.61%18.14%5.12%16.35%11.71%18.27%
Free Cash Flow Margin
8.72%6.80%8.27%10.70%2.70%-13.39%
EBITDA
225.21212.67150.01165.35151.54144.29
EBITDA Margin
24.56%23.24%18.17%17.97%17.48%17.82%
D&A For EBITDA
35.1429.531.2435.832.0331.78
EBIT
190.07183.17118.77129.54119.51112.51
EBIT Margin
20.73%20.02%14.39%14.08%13.79%13.89%
Effective Tax Rate
13.54%10.68%44.60%-11.70%11.34%
Revenue as Reported
454.25915.12825.4920.01866.73809.78
Advertising Expenses
----32.55350.29